(BRC) Brady - Ratings and Ratios
Safety Signs, Labeling Systems, RFID Tags, Patient Wristbands, Access Badges
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.68% |
| Yield on Cost 5y | 1.96% |
| Yield CAGR 5y | 2.19% |
| Payout Consistency | 96.6% |
| Payout Ratio | 20.7% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 22.0% |
| Value at Risk 5%th | 32.3% |
| Relative Tail Risk | -10.67% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.47 |
| Alpha | 0.14 |
| CAGR/Max DD | 1.18 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.466 |
| Beta | 0.663 |
| Beta Downside | 0.621 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.98% |
| Mean DD | 5.17% |
| Median DD | 4.84% |
Description: BRC Brady January 11, 2026
Brady Corporation (NYSE:BRC) designs, manufactures, and distributes a broad portfolio of identification and workplace-safety solutions-including safety signs, lockout/tagout devices, RFID/barcode scanners, and handheld printers-serving industrial, healthcare, aerospace, and government customers across the Americas, Europe, Asia, and Australia.
The company reaches end-users through a hybrid go-to-market model that blends independent distributors, a direct sales force, and expanding digital channels, allowing it to capture both high-volume commodity sales and higher-margin custom solutions.
Key financial snapshots (FY 2023): revenue ≈ $1.73 billion, operating margin ≈ 12.5 %, free-cash-flow conversion ≈ 85 %, and a dividend yield of roughly 2.4 %. The balance sheet is solid, with a debt-to-equity ratio of 0.45 and a return on invested capital (ROIC) near 13 %.
Primary growth catalysts include tightening occupational-health-and-safety regulations (e.g., OSHA and EU directives), accelerating adoption of RFID and barcode technologies in supply-chain digitization, and rising capital-expenditure cycles in infrastructure, renewable-energy, and automotive sectors-all of which boost demand for labeling, asset-tracking, and compliance-software services.
Investors seeking a deeper, data-driven assessment of Brady’s valuation and risk profile may find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (196.4m TTM) > 0 and > 6% of Revenue (6% = 92.5m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 0.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.16% (prev 18.36%; Δ 3.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 191.1m <= Net Income 196.4m (YES >=105%, WARN >=100%) |
| Net Debt (-5.90m) to EBITDA (292.9m) ratio: -0.02 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (47.7m) change vs 12m ago -1.01% (target <= -2.0% for YES) |
| Gross Margin 50.59% (prev 50.90%; Δ -0.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 90.10% (prev 85.17%; Δ 4.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 54.66 (EBITDA TTM 292.9m / Interest Expense TTM 4.60m) >= 6 (WARN >= 3) |
Altman Z'' 7.14
| (A) 0.19 = (Total Current Assets 662.4m - Total Current Liabilities 320.7m) / Total Assets 1.79b |
| (B) 0.76 = Retained Earnings (Balance) 1.36b / Total Assets 1.79b |
| (C) 0.15 = EBIT TTM 251.4m / Avg Total Assets 1.71b |
| (D) 2.32 = Book Value of Equity 1.27b / Total Liabilities 549.9m |
| Total Rating: 7.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 81.84
| 1. Piotroski 5.50pt |
| 2. FCF Yield 4.12% |
| 3. FCF Margin 10.37% |
| 4. Debt/Equity 0.14 |
| 5. Debt/Ebitda -0.02 |
| 6. ROIC - WACC (= 7.42)% |
| 7. RoE 16.63% |
| 8. Rev. Trend 85.97% |
| 9. EPS Trend 91.81% |
What is the price of BRC shares?
Over the past week, the price has changed by +1.75%, over one month by +2.48%, over three months by +12.46% and over the past year by +16.24%.
Is BRC a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BRC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96 | 16.8% |
| Analysts Target Price | 96 | 16.8% |
| ValueRay Target Price | 94.6 | 15.1% |
BRC Fundamental Data Overview January 10, 2026
P/E Forward = 13.3511
P/S = 2.5188
P/B = 3.0512
P/EG = 2.5
Beta = 0.649
Revenue TTM = 1.54b USD
EBIT TTM = 251.4m USD
EBITDA TTM = 292.9m USD
Long Term Debt = 115.9m USD (from longTermDebt, last quarter)
Short Term Debt = 16.6m USD (from shortTermDebt, last quarter)
Debt = 176.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.90m USD (from netDebt column, last quarter)
Enterprise Value = 3.88b USD (3.88b + Debt 176.8m - CCE 182.7m)
Interest Coverage Ratio = 54.66 (Ebit TTM 251.4m / Interest Expense TTM 4.60m)
EV/FCF = 24.25x (Enterprise Value 3.88b / FCF TTM 159.9m)
FCF Yield = 4.12% (FCF TTM 159.9m / Enterprise Value 3.88b)
FCF Margin = 10.37% (FCF TTM 159.9m / Revenue TTM 1.54b)
Net Margin = 12.74% (Net Income TTM 196.4m / Revenue TTM 1.54b)
Gross Margin = 50.59% ((Revenue TTM 1.54b - Cost of Revenue TTM 761.9m) / Revenue TTM)
Gross Margin QoQ = 51.53% (prev 50.40%)
Tobins Q-Ratio = 2.16 (Enterprise Value 3.88b / Total Assets 1.79b)
Interest Expense / Debt = 0.68% (Interest Expense 1.21m / Debt 176.8m)
Taxrate = 21.23% (14.5m / 68.5m)
NOPAT = 198.0m (EBIT 251.4m * (1 - 21.23%))
Current Ratio = 2.07 (Total Current Assets 662.4m / Total Current Liabilities 320.7m)
Debt / Equity = 0.14 (Debt 176.8m / totalStockholderEquity, last quarter 1.24b)
Debt / EBITDA = -0.02 (Net Debt -5.90m / EBITDA 292.9m)
Debt / FCF = -0.04 (Net Debt -5.90m / FCF TTM 159.9m)
Total Stockholder Equity = 1.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.48% (Net Income 196.4m / Total Assets 1.79b)
RoE = 16.63% (Net Income TTM 196.4m / Total Stockholder Equity 1.18b)
RoCE = 19.38% (EBIT 251.4m / Capital Employed (Equity 1.18b + L.T.Debt 115.9m))
RoIC = 15.43% (NOPAT 198.0m / Invested Capital 1.28b)
WACC = 8.02% (E(3.88b)/V(4.06b) * Re(8.36%) + D(176.8m)/V(4.06b) * Rd(0.68%) * (1-Tc(0.21)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 79.63% ; FCFF base≈152.0m ; Y1≈170.6m ; Y5≈227.4m
Fair Price DCF = 89.57 (EV 3.90b - Net Debt -5.90m = Equity 3.91b / Shares 43.6m; r=8.02% [WACC]; 5y FCF grow 14.16% → 2.90% )
EPS Correlation: 91.81 | EPS CAGR: 15.71% | SUE: 0.77 | # QB: 0
Revenue Correlation: 85.97 | Revenue CAGR: 6.68% | SUE: 1.04 | # QB: 2
EPS next Quarter (2026-04-30): EPS=1.35 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-07-31): EPS=5.04 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+9.7% | Growth Revenue=+6.0%
EPS next Year (2027-07-31): EPS=5.50 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+8.9% | Growth Revenue=+3.8%
Additional Sources for BRC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle